The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor
Open accessAbstract
In order to establish the structural requirements for binding to the brain cannabinoid receptor (CB1), we have synthesized numerous fatty acid amides, ethanolamides, and some related simple derivatives and have determined their Ki values. A few alpha-methyl- or alpha, alpha-dimethylarachidonoylalkylamides were also examined. In the 20:4, n-6 series, the unsubstituted amide is inactive; N-monoalkylation, at least up to a branched pentyl group, leads to significant binding. N,N-Dialkylation, with or without hydroxylation on one of the alkyl groups, leads to elimination of activity. Hydroxylation of the N-monoalkyl group at the omega carbon atom retains activity. In the 20x, n-6 series, x has to be either 3 or 4; the presence of only two double bonds leads to inactivation. In the n-3 series, the limited data reported suggest that the derived ethanolamides are either inactive or less active than comparable compounds in the n-6 series. Alkylation or dialkylation of the alpha carbon adjacent to the carbonyl group retains the level of binding in the case of anandamide (compounds 48, 49); however, alpha-monomethylation or alpha,alpha-dimethylation of N-propyl derivatives (50-53) potentiates binding and leads to the most active compounds seen in the present work (Ki values of 6.9 +/- 0.7 to 8.4 +/- 1.1 nM). We have confirmed that the presence of a chiral center on the N-alkyl substituent may lead to enantiomers which differ in their levels of binding (compounds 54, 57 and 55, 56).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Self-citationIsolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
Self-citationFormation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Recognition of a lipid antigen by CD1-restricted αβ+ T cells
Beckman, E. M., Porcelli, S. A., Morita, C. T., Behar, S. M., Furlong, S. T., & Brenner, M. B. (1994) · Nature · doi:10.1038/372691a0 · Cited by 978
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
Deutsch, D. G., & Chin, S. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90486-g · Cited by 702
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
Chemical characterization of a family of brain lipids that induce sleep
Cravatt, B. F., Prospero-Garcia, O., Siuzdak, G., Gilula, N. B., Henriksen, S. J., Boger, D. L., & Lerner, R. A. (1995) · Science · doi:10.1126/science.7770779 · Cited by 620
Felder, C. C., Briley, E. M., Axelrod, J., Simpson, J. T., Mackie, K., & Devane, W. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7656 · Cited by 475
N-Acylated glycerophospholipids and their derivatives
Schmid, H. H. O., Schmid, P. C., & Natarajan, V. (1990) · Progress in Lipid Research · doi:10.1016/0163-7827(90)90004-5 · Cited by 451
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent
Fride, E., & Mechoulam, R. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90468-w · Cited by 451
Self-citation
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Self-citationPharmacological Actions of Cannabinoids
Pertwee, R. G. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_1 · Cited by 597
Cannabinoid receptors and their ligands
Pertwee, R. G., & Ross, R. A. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0341 · Cited by 561
Howlett, A. C. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00060-6 · Cited by 535
A biosynthetic pathway for anandamide
Liu, J., Wang, L., Harvey-White, J., Osei-Hyiaman, D., Razdan, R., Gong, Q., Chan, A. C., Zhou, Z., Huang, B. X., Kim, H.-Y., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601832103 · Cited by 470
Mechoulam, R., Fride, E., & Di Marzo, V. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00649-9 · Cited by 428
Self-citationCANNABINOID RECEPTORS AND THEIR ENDOGENOUS AGONISTS
Felder, C. C., & Glass, M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.179 · Cited by 390
Mechanisms of Exercise-Induced Hypoalgesia
Koltyn, K. F., Brellenthin, A. G., Cook, D. B., Sehgal, N., & Hillard, C. (2014) · The Journal of Pain · doi:10.1016/j.jpain.2014.09.006 · Cited by 382
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Huang, S. M., Bisogno, T., Petros, T. J., Chang, S. Y., Zavitsanos, P. A., Zipkin, R. E., Sivakumar, R., Coop, A., Maeda, D. Y., De Petrocellis, L., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107351200 · Cited by 339
McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., & Bradshaw, H. B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-44 · Cited by 323
Self-citationDi Marzo, V. (1998) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(98)00042-3 · Cited by 312
Endocannabinoids and Their Pharmacological Actions
Pertwee, R. G. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-20825-1_1 · Cited by 300
A historical overview of chemical research on cannabinoids
Mechoulam, R., & Hanuš, L. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00184-5 · Cited by 282
Self-citationHo, W., Barrett, D. A., & Randall, M. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.324 · Cited by 259
Re, G., Barbero, R., Miolo, A., & Di Marzo, V. (2007) · The Veterinary Journal · doi:10.1016/j.tvjl.2005.10.003 · Cited by 199
T-Type Calcium Channel Inhibition Underlies the Analgesic Effects of the Endogenous Lipoamino Acids
Barbara, G., Alloui, A., Nargeot, J., Lory, P., Eschalier, A., Bourinet, E., & Chemin, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2919-09.2009 · Cited by 125
Actions of N-arachidonyl-glycine in a rat neuropathic pain model
Vuong, L. A. Q., Mitchell, V. A., & Vaughan, C. W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.004 · Cited by 89
Wood, J. T., Williams, J. S., Pandarinathan, L., Courville, A., Keplinger, M. R., Janero, D. R., Vouros, P., Makriyannis, A., & Lammi-Keefe, C. J. (2008) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2008.242 · Cited by 71
Asaro, A., Carlo‐Spiewok, A., Malik, A. R., Rothe, M., Schipke, C. G., Peters, O., Heeren, J., & Willnow, T. E. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12121 · Cited by 38
Metadata
- Authors
- Sheskin, T., Hanuš, L., Slager, J., Vogel, Z., & Mechoulam, R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1997-02-01
- Volume
- 40
- Issue
- 5
- Pages
- 659-667
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1975161769
- Cited by
- 275
- References
- 34
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.